{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:25:52Z","timestamp":1782512752710,"version":"3.54.5"},"reference-count":124,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1097\/cad.0b013e3283293fd4","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T10:07:04Z","timestamp":1242900424000},"page":"217-229","source":"Crossref","is-referenced-by-count":36,"title":["Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer"],"prefix":"10.1097","volume":"20","author":[{"given":"Giuseppe","family":"Aprile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micol","family":"Mazzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Moroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210203","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.bcp.2004.07.005","article-title":"Prodrug research: futile or fertile?","volume":"68","author":"Testa","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"R2-1-20210203","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.2165\/00003495-200161150-00015","article-title":"Capecitabine: a review of its use in the treatment of advanced breast or metastatic colorectal cancer","volume":"61","author":"McGavin","year":"2001","journal-title":"Drugs"},{"key":"R3-1-20210203","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1634\/theoncologist.12-4-375","article-title":"Capecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trials","volume":"12","author":"Tripathy","year":"2007","journal-title":"Oncologist"},{"key":"R4-1-20210203","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2165\/00003495-200868070-00005","article-title":"Capecitabine, alone and in combination, in the management of patients with colorectal cancer: a review of the evidence","volume":"68","author":"Comella","year":"2008","journal-title":"Drugs"},{"key":"R5-1-20210203","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00003495-199958010-00006","article-title":"Capecitabine","volume":"58","author":"Dooley","year":"1999","journal-title":"Drugs"},{"key":"R6-1-20210203","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur J Cancer"},{"key":"R7-1-20210203","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0006-2952(97)00682-5","article-title":"Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts","volume":"55","author":"Ishikawa","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"R8-1-20210203","first-page":"72","article-title":"Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy","volume":"27","author":"Sobrero","year":"2000","journal-title":"Semin Oncol"},{"key":"R9-1-20210203","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1200\/JCO.1998.16.5.1795","article-title":"Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine","volume":"16","author":"Budman","year":"1998","journal-title":"J Clin Oncol"},{"key":"R10-1-20210203","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.1998.16.9.2977","article-title":"Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and\/or metastatic cancer","volume":"16","author":"Mackean","year":"1998","journal-title":"J Clin Oncol"},{"key":"R11-1-20210203","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","article-title":"Clinical pharmacokinetics of capecitabine","volume":"40","author":"Reigner","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"R12-1-20210203","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1006263400888","article-title":"A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug","volume":"17","author":"Judson","year":"1999","journal-title":"Invest New Drugs"},{"key":"R13-1-20210203","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00280-001-0408-0","article-title":"Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients","volume":"49","author":"Poole","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"R14-1-20210203","first-page":"1696","article-title":"Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites","volume":"5","author":"Twelves","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R15-1-20210203","first-page":"12","article-title":"Drug interaction of capecitabine and phenytoin in the therapy of cerebral and visceral metastatic breast cancer","volume":"11","author":"Schaller","year":"2000","journal-title":"Ann Oncol"},{"key":"R16-1-20210203","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3816\/CCC.2001.n.019","article-title":"An adverse interaction between warfarin and capecitabine: a case report and review of the literature","volume":"1","author":"Copur","year":"2001","journal-title":"Clin Colorectal Cancer"},{"key":"R17-1-20210203","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3816\/CCC.2006.n.006","article-title":"A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin","volume":"5","author":"Shah","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"R18-1-20210203","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1200\/JCO.2005.09.129","article-title":"Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer","volume":"23","author":"Camidge","year":"2005","journal-title":"J Clin Oncol"},{"key":"R19-1-20210203","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0090-9556(24)15065-9","article-title":"Prediction of in vivo drug-drug interactions based on mechanism-based inhibition from invivo data: inhibition of 5-fluorouracil metabolism by (E)-5-(2-bromovinyl)uracil","volume":"28","author":"Kanamitsu","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"R20-1-20210203","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1200\/JCO.2007.15.9426","article-title":"Severe sequence-specific toxicity when capecitabine is given after fluorouracil and leucovorin","volume":"26","author":"Henning","year":"2008","journal-title":"J Clin Oncol"},{"key":"R21-1-20210203","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2165\/00002512-200724050-00004","article-title":"Oral anticancer drugs in the elderly: an overview","volume":"24","author":"Lonardi","year":"2007","journal-title":"Drugs Aging"},{"key":"R22-1-20210203","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1200\/JCO.2005.02.167","article-title":"Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women","volume":"23","author":"Bajetta","year":"2005","journal-title":"J Clin Oncol"},{"key":"R23-1-20210203","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1159\/000086996","article-title":"Phase II study of an \u2018all-oral\u2019 regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer-safety, efficacy and quality of life","volume":"68","author":"Tong","year":"2005","journal-title":"Oncology"},{"key":"R24-1-20210203","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000127414","article-title":"Capecitabine and vinorelbine as first-line treatment in elderly patients (\u226565 years) with metastatic breast cancer. A phase II trial (SAKK 25\/99)","volume":"73","author":"Hess","year":"2007","journal-title":"Oncology"},{"issue":"Suppl","key":"R25-1-20210203","doi-asserted-by":"crossref","first-page":"s507","DOI":"10.1200\/jco.2008.26.15_suppl.507","article-title":"Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: results of CALGB\/CTSU 49907","volume":"26","author":"Muss","year":"2008","journal-title":"J Clin Oncol"},{"key":"R26-1-20210203","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa010957","article-title":"A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients","volume":"345","author":"Sargent","year":"2001","journal-title":"N Engl J Med"},{"key":"R27-1-20210203","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2006.06.9039","article-title":"Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil\/leucovorin administered bimonthly in elderly patients with colorectal cancer","volume":"24","author":"Goldberg","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"R28-1-20210203","doi-asserted-by":"crossref","first-page":"s797","DOI":"10.1200\/jco.2004.22.90140.797","article-title":"Capecitabine monotherapy for elderly patients with metastatic breast cancer","volume":"22","author":"Minea","year":"2004","journal-title":"J Clin Oncol"},{"key":"R29-1-20210203","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J Clin Oncol"},{"key":"R30-1-20210203","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/annonc\/mdf089","article-title":"Capecitabine colorectal cancer study group first-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin","volume":"13","author":"Cassidy","year":"2002","journal-title":"Ann Oncol"},{"key":"R31-1-20210203","first-page":"3114","article-title":"A study of capecitabine in elderly patients as first line treatment in advanced or metastatic colorectal cancer","volume":"22","author":"Escudero","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl","key":"R32-1-20210203","first-page":"768","article-title":"Preservation of activities of daily living (ADL) in a phase-II impact study of oral capecitabine and vinorelbine in the treatment of metastatic carcinomas in patients 70 and older: the GERICO-01 Study by the French FNCLCC Group","volume":"22","author":"Braud","year":"2004","journal-title":"J Clin Oncol"},{"key":"R33-1-20210203","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3816\/CCC.2005.n.021","article-title":"Capecitabine\/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study","volume":"5","author":"Twelves","year":"2005","journal-title":"Clin Colorectal Cancer"},{"key":"R34-1-20210203","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.critrevonc.2005.08.006","article-title":"Capecitabine use in geriatric oncology: an analysis of current safety, efficacy, and quality of life data","volume":"58","author":"Ershler","year":"2006","journal-title":"Crit Rev Hematol Oncol"},{"key":"R35-1-20210203","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00520-003-0550-9","article-title":"Gastrointestinal mucositis: a new biological model","volume":"12","author":"Keefe","year":"2004","journal-title":"Support Care Cancer"},{"key":"R36-1-20210203","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/CAD.0b013e3282f945aa","article-title":"Capecitabine: an overview of the side effects and their management","volume":"19","author":"Saif","year":"2008","journal-title":"Anticancer Drugs"},{"key":"R37-1-20210203","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejon.2004.06.006","article-title":"Management of adverse events and other practical considerations in patients reciving capecitabine (Xeloda)","volume":"8","author":"Mars\u00e9","year":"2004","journal-title":"Eur J Oncol Nurs"},{"key":"R38-1-20210203","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1634\/theoncologist.10-2-104","article-title":"Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development","volume":"10","author":"Lee","year":"2005","journal-title":"Oncologist"},{"key":"R39-1-20210203","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3816\/CCC.2004.n.018","article-title":"DPD deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration","volume":"4","author":"Ezzledin","year":"2004","journal-title":"Clin Colorectal Cancer"},{"key":"R40-1-20210203","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/07357900500524702","article-title":"Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question","volume":"24","author":"Van Kluiberg","year":"2006","journal-title":"Cancer Invest"},{"key":"R41-1-20210203","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-59745-205-2_5","article-title":"Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy","volume":"448","author":"Bosch","year":"2008","journal-title":"Methods Mol Biol"},{"key":"R42-1-20210203","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3816\/CCC.2006.n.047","article-title":"Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil\/capecitabine therapy","volume":"6","author":"Mercier","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"R43-1-20210203","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2125.2008.03159.x","article-title":"Candidate mechanisms for capecitabine-related hand-foot syndrome","volume":"66","author":"Milano","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"R44-1-20210203","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3816\/SCT.2007.n.017","article-title":"Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dyhydropyrimidine dehydrogenase: is there a pharmacologic explanation?","volume":"4","author":"Saif","year":"2007","journal-title":"Supp Cancer Ther"},{"key":"R45-1-20210203","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1158\/1078-0432.CCR-07-1225","article-title":"Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?","volume":"14","author":"Yen-Revollo","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R46-1-20210203","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2165\/00003495-199957040-00003","article-title":"Cardiotoxicity of the antiproliferative compound fluorouracil","volume":"57","author":"Becker","year":"1999","journal-title":"Drugs"},{"key":"R47-1-20210203","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/annonc\/mdh150","article-title":"5-Fluorouracil induces arterial vasocontractions","volume":"15","author":"Sudhoff","year":"2004","journal-title":"Ann Oncol"},{"key":"R48-1-20210203","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2459\/01.JCM.0000250874.09273.9b","article-title":"A case of acute myocardial infarction during 5-fluorouracil infusion","volume":"7","author":"Canale","year":"2006","journal-title":"J Cardiovasc Med"},{"key":"R49-1-20210203","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","article-title":"Capecitabine: a review","volume":"27","author":"Walko","year":"2005","journal-title":"Clin Ther"},{"key":"R50-1-20210203","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"R51-1-20210203","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/annonc\/mdf035","article-title":"Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil","volume":"13","author":"Frickofen","year":"2002","journal-title":"Ann Oncol"},{"key":"R52-1-20210203","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1634\/theoncologist.11-4-325","article-title":"Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer","volume":"11","author":"Ershler","year":"2006","journal-title":"Oncologist"},{"key":"R53-1-20210203","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-004-1282-3","article-title":"Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program","volume":"88","author":"Pierga","year":"2004","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl","key":"R54-1-20210203","doi-asserted-by":"crossref","first-page":"s1031","DOI":"10.1200\/jco.2007.25.18_suppl.1031","article-title":"A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC)","volume":"25","author":"Stockler","year":"2007","journal-title":"J Clin Oncol"},{"key":"R55-1-20210203","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"J Clin Oncol"},{"key":"R56-1-20210203","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel in combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results","volume":"20","author":"O'Shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"key":"R57-1-20210203","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/annonc\/mdl134","article-title":"Detailed analysis of a randomized Phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage?","volume":"17","author":"Leonard","year":"2006","journal-title":"Ann Oncol"},{"key":"R58-1-20210203","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1200\/JCO.2004.12.128","article-title":"Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study","volume":"22","author":"Gradishar","year":"2004","journal-title":"J Clin Oncol"},{"key":"R59-1-20210203","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3816\/CBC.2006.n.023","article-title":"Phase II study of weekly docetaxel and capecitabine in patients with metastatic breast cancer","volume":"7","author":"Mrozek","year":"2006","journal-title":"Clin Breast Cancer"},{"key":"R60-1-20210203","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1200\/JCO.2005.05.1383","article-title":"Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer","volume":"24","author":"Blum","year":"2006","journal-title":"J Clin Oncol"},{"key":"R61-1-20210203","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000100449","article-title":"Efficacy and tolerability of capecitabine with weekly paclitaxel for patients with metastatic breast cancer: a phase II report of the SAKK","volume":"71","author":"Gick","year":"2006","journal-title":"Oncology"},{"key":"R62-1-20210203","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdn165","article-title":"Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer","volume":"19","author":"Puglisi","year":"2008","journal-title":"Ann Oncol"},{"issue":"4","key":"R63-1-20210203","first-page":"s143a","article-title":"Capecitabine combined with trastuzumab in the therapy of intensively pre-treated HER2-overexpressing metastatic breast cancer (MBC)","volume":"11","author":"Bangemann","year":"2000","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"R64-1-20210203","doi-asserted-by":"crossref","first-page":"s10615","DOI":"10.1200\/jco.2006.24.18_suppl.10615","article-title":"A phase II trial of trastuzumab (H) +capecitabine (X) as first-line treatment in patients (pts) with HER2-positive metastatic breast cancer","volume":"24","author":"Xu","year":"2006","journal-title":"J Clin Oncol"},{"key":"R65-1-20210203","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2006.09.6826","article-title":"Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes","volume":"25","author":"Schaller","year":"2007","journal-title":"J Clin Oncol"},{"key":"R66-1-20210203","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.2007.11.9776","article-title":"Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer","volume":"25","author":"Bartsch","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"R67-1-20210203","doi-asserted-by":"crossref","first-page":"s1117","DOI":"10.1200\/jco.2008.26.15_suppl.1117","article-title":"Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2-overexpressing metastatic breast cancers after failure of both anthracyclines and taxanes","volume":"26","author":"Ishida","year":"2008","journal-title":"J Clin Oncol"},{"key":"R68-1-20210203","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00280-007-0497-5","article-title":"A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial","volume":"61","author":"Yamamoto","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"R69-1-20210203","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00280-007-0586-5","article-title":"Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer","volume":"62","author":"Osako","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"R70-1-20210203","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","article-title":"Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer","volume":"23","author":"Miller","year":"2005","journal-title":"J Clin Oncol"},{"key":"R71-1-20210203","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study","volume":"19","author":"Van Cutsem","year":"2001","journal-title":"J Clin Oncol"},{"key":"R72-1-20210203","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","article-title":"Capecitabine as adjuvant treatment for stage III colon cancer","volume":"352","author":"Twelves","year":"2005","journal-title":"N Engl J Med"},{"key":"R73-1-20210203","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0959-8049(00)00444-5","article-title":"Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma","volume":"37","author":"Twelves","year":"2001","journal-title":"Eur J Cancer"},{"key":"R74-1-20210203","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/annonc\/mdg500","article-title":"On behalf of the X-ACT Study Group; oral capecitabine as an alternative to iv 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial","volume":"14","author":"Scheithauer","year":"2003","journal-title":"Ann Oncol"},{"key":"R75-1-20210203","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2006.09.8467","article-title":"Phase III study of capecitabine plus oxaliplatin versus continuous infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors trial","volume":"25","author":"Diaz-Rubio","year":"2007","journal-title":"J Clin Oncol"},{"key":"R76-1-20210203","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2006.09.2684","article-title":"Capecitabine plus oxaliplatin versus 5-fluorouracil\/leucovorin plus oxaliplatin: a randomized comparison in metastatic colorectal cancer","volume":"25","author":"Porschen","year":"2007","journal-title":"J Clin Oncol"},{"key":"R77-1-20210203","first-page":"272","article-title":"Preliminary efficacy findings from a randomized phase III study of capecitabine+oxaliplatin (XELOX) vs. infusional 5-FU\/LV+oxaliplatin (FOLFOX-6) as first line treatment for metastatic colorectal cancer (MCRC)","volume":"220","author":"Bennouna","year":"2007","journal-title":"Gastrointestinal Cancers Symposium"},{"key":"R78-1-20210203","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","article-title":"Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer","volume":"26","author":"Cassidy","year":"2008","journal-title":"J Clin Oncol"},{"key":"R79-1-20210203","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.2007.15.4138","article-title":"Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study","volume":"26","author":"Hochster","year":"2008","journal-title":"J Clin Oncol"},{"key":"R81-1-20210203","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2007.11.6582","article-title":"Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?","volume":"25","author":"Mayer","year":"2007","journal-title":"J Clin Oncol"},{"key":"R82-1-20210203","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2006.08.1075","article-title":"Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1864 patients","volume":"25","author":"Schmoll","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"R83-1-20210203","doi-asserted-by":"crossref","first-page":"s517","DOI":"10.1200\/jco.2006.24.18_suppl.517","article-title":"Epirubicin\/paclitaxel (EP) vs. capecitabine\/paclitaxel (XP) in first-line metastatic breast cancer (MBC): a prospective, randomized, multicentre phase III study of the AGO breast cancer study group","volume":"24","author":"Lueck","year":"2006","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"R84-1-20210203","doi-asserted-by":"crossref","first-page":"s1025","DOI":"10.1200\/jco.2008.26.15_suppl.1025","article-title":"Capecitabine v capecitabine+trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG26\/BIG 3-05)","volume":"26","author":"Von Minckwitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"R85-1-20210203","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"R86-1-20210203","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2007.12.6557","article-title":"Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"R87-1-20210203","doi-asserted-by":"crossref","first-page":"s20","DOI":"10.1634\/theoncologist.11-90001-20","article-title":"Capecitabine: expanding options for the treatment of patients with early or locally advanced breast cancer","volume":"11","author":"Wardley","year":"2006","journal-title":"Oncologist"},{"key":"R88-1-20210203","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","article-title":"Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients","volume":"92","author":"Blum","year":"2001","journal-title":"Cancer"},{"key":"R89-1-20210203","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1023\/A:1012281104865","article-title":"Randomized, openlabel, phase II trial of oral capecitabine (Xeloda) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced\/metastatic breast cancer","volume":"12","author":"O'Shaughnessy","year":"2001","journal-title":"Ann Oncol"},{"key":"R90-1-20210203","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.bjc.6600261","article-title":"Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic\/advanced breast cancer pretreated with anthracyclines","volume":"86","author":"Talbot","year":"2002","journal-title":"Br J Cancer"},{"key":"R91-1-20210203","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejca.2003.11.007","article-title":"Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer","volume":"40","author":"Fumoleau","year":"2004","journal-title":"Eur J Cancer"},{"key":"R92-1-20210203","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/annonc\/mdg346","article-title":"Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane containing therapy","volume":"14","author":"Reichardt","year":"2003","journal-title":"Ann Oncol"},{"key":"R93-1-20210203","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/02841860310023165","article-title":"Oral capecitabine in anthracycline- and taxane-pretreated advanced\/metastatic breast cancer","volume":"43","author":"Wist","year":"2004","journal-title":"Acta Oncol"},{"key":"R94-1-20210203","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000111094","article-title":"An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breas cancer","volume":"72","author":"Venturini","year":"2007","journal-title":"Oncology"},{"key":"R97-1-20210203","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2152\/jmi.55.54","article-title":"Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results","volume":"55","author":"Honda","year":"2008","journal-title":"J Med Invest"},{"key":"R98-1-20210203","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00024669-200605020-00004","article-title":"First-line treatment of metastatic breast cancer: available evidence and current recommendations","volume":"5","author":"Puglisi","year":"2006","journal-title":"Am J Cancer"},{"key":"R99-1-20210203","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clon.2007.06.016","article-title":"Improving adjuvant chemotherapy in breast cancer \u2013 can we get more for less with TACT2?","volume":"19","author":"Johnson","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R100-1-20210203","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3816\/CBC.2002.n.004","article-title":"Taxanes and capecitabine in combination: rationale and clinical results","volume":"2","author":"Maher","year":"2002","journal-title":"Clin Breast Cancer"},{"key":"R101-1-20210203","first-page":"1013","article-title":"Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol\/taxotere in human cancer xenografts","volume":"4","author":"Sawada","year":"1998","journal-title":"Clin Cancer Res"},{"key":"R102-1-20210203","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1038\/sj.bjc.6601845","article-title":"Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer","volume":"90","author":"Toi","year":"2004","journal-title":"Br J Cancer"},{"key":"R103-1-20210203","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/CAD.0b013e32816ebede","article-title":"Anthracyclines and taxanes induce the upregulation of thymidine phosphorylase in breast cancer cells","volume":"18","author":"Puglisi","year":"2007","journal-title":"Anticancer Drugs"},{"key":"R104-1-20210203","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3816\/CBC.2004.n.030","article-title":"Survival benefit with capecitabine\/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial","volume":"5","author":"Miles","year":"2004","journal-title":"Clin Breast Cancer"},{"key":"R105-1-20210203","doi-asserted-by":"crossref","first-page":"581a","DOI":"10.1200\/jco.2005.23.16_suppl.581","article-title":"Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study","volume":"23","author":"Chan","year":"2005","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R106-1-20210203","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1038\/sj.bjc.6601784","article-title":"Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced\/metastatic breast cancer","volume":"90","author":"Batista","year":"2004","journal-title":"Br J Cancer"},{"issue":"Suppl","key":"R107-1-20210203","doi-asserted-by":"crossref","first-page":"s1119","DOI":"10.1200\/jco.2008.26.15_suppl.1119","article-title":"Navcap (vinorelbine and capecitabine) versus navcap followed by weekly docetaxel as first-line treatment in metastatic breast cancer patients: a randomized multicenter phase II trial","volume":"26","author":"Ghosn","year":"2008","journal-title":"J Clin Oncol"},{"key":"R108-1-20210203","first-page":"2451","article-title":"Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients","volume":"26","author":"Ghosn","year":"2006","journal-title":"Anticancer Research"},{"key":"R109-1-20210203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00280-007-0565-x","article-title":"Sequential vinorelbine-capecitabine followed by docetaxel in advanced breast cancer: long term-results of a pilot phase II trial","volume":"62","author":"Ghosn","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Suppl","key":"R110-1-20210203","doi-asserted-by":"crossref","first-page":"s1056","DOI":"10.1200\/jco.2007.25.18_suppl.1056","article-title":"An international phase II study of an all-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC)","volume":"25","author":"Tubiana-Mathieu","year":"2007","journal-title":"J Clin Oncol"},{"key":"R111-1-20210203","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3816\/CBC.2005.n.018","article-title":"Gemcitabine\/capecitabine in patients with metastatic breast cancer pretrseated with anthracyclines and taxanes","volume":"6","author":"Andres","year":"2005","journal-title":"Clin Breast Cancer"},{"issue":"Suppl","key":"R112-1-20210203","doi-asserted-by":"crossref","first-page":"s1051","DOI":"10.1200\/jco.2007.25.18_suppl.1051","article-title":"Multicentric phase II trial of gemcitabine plus capecitabine combination in the treatment of previously anthracycline (An)-treated metastatic breast cancer (MBC): SOLTI 0301 Study","volume":"25","author":"Ciruelos","year":"2007","journal-title":"J Clin Oncol"},{"key":"R113-1-20210203","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1158\/1078-0432.CCR-08-0015","article-title":"Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies","volume":"14","author":"Lechleider","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R115-1-20210203","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1200\/JCO.2008.17.4789","article-title":"Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer","volume":"26","author":"Dellapasqua","year":"2008","journal-title":"J Clin Oncol"},{"key":"R116-1-20210203","first-page":"413","article-title":"DPD is a molecular determinant of capecitabine efficacy in colorectal cancer","volume":"31","author":"Vallbohmer","year":"2008","journal-title":"Int J Oncol"},{"key":"R119-1-20210203","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1586\/14737140.8.2.161","article-title":"Capecitabine plus oxaliplatin for the treatment of colorectal cancer","volume":"8","author":"Carrato","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"R120-1-20210203","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.2007.15.9640","article-title":"Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer","volume":"26","author":"Punt","year":"2008","journal-title":"J Clin Oncol"},{"key":"R121-1-20210203","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/annonc\/mdi047","article-title":"A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity","volume":"16","author":"Borner","year":"2005","journal-title":"Ann Oncol"},{"key":"R122-1-20210203","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cncr.11910","article-title":"Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma","volume":"100","author":"Bajetta","year":"2004","journal-title":"Cancer"},{"key":"R123-1-20210203","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.clon.2007.11.008","article-title":"Efficacy of combination chemotherapy with irinotecan (CPT-11) plus capecitabine in patients with metastatic or advanced colorectal carcinoma-a dual-centre phase II study: the MAC-6","volume":"20","author":"Choi","year":"2008","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R124-1-20210203","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/COC.0b013e31804b40bb","article-title":"Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results","volume":"30","author":"Patt","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"R125-1-20210203","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1200\/JCO.2005.05.2084","article-title":"Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer","volume":"24","author":"Meropol","year":"2006","journal-title":"J Clin Oncol"},{"key":"R126-1-20210203","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1200\/JCO.2007.11.3357","article-title":"Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study","volume":"25","author":"Fuchs","year":"2007","journal-title":"J Clin Oncol"},{"key":"R127-1-20210203","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdm544","article-title":"Irinotecan combined with infusional 5-fluorouracil\/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC Study 40015","volume":"19","author":"K\u00f6hne","year":"2008","journal-title":"Ann Oncol"},{"key":"R129-1-20210203","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patient preferences for oral versus intravenous palliative chemotherapy","volume":"15","author":"Liu","year":"1997","journal-title":"J Clin Oncol"},{"key":"R130-1-20210203","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0959-8049(01)00371-9","article-title":"Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer","volume":"38","author":"Borner","year":"2002","journal-title":"Eur J Cancer"},{"key":"R131-1-20210203","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/annonc\/mdj023","article-title":"A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil\/leucovorin regimens in patients with advanced colorectal cancer","volume":"17","author":"Twelves","year":"2006","journal-title":"Ann Oncol"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CAD.0b013e3283293fd4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T16:39:22Z","timestamp":1739119162000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001813-200904000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":124,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e3283293fd4","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}